Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspirates
Adeeti V Ullal1, Vanessa Peterson, Sarit S Agasti
1Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge Street, CPZN 5206, Boston, MA 02114, USA.
Science Translational Medicine
|January 17, 2014
Summary
This study introduces a new DNA-barcoded antibody technology for analyzing hundreds of proteins from fine-needle aspirates (FNAs). This advancement enables single-cell cancer diagnosis and drug response prediction with high reproducibility.
Area of Science:
- Biotechnology
- Cancer Research
- Molecular Diagnostics
Background:
- Current immunohistochemistry methods for cancer diagnosis rely on invasive core biopsies and limited protein markers.
- Fine-needle aspirates (FNAs) offer a less invasive diagnostic approach but contain fewer cells, limiting traditional protein analysis.
Purpose of the Study:
- To develop and validate a novel technology for high-throughput proteomic analysis of FNAs.
- To enable single-cell protein profiling for detailed cancer characterization and drug response prediction.
Main Methods:
- Utilized DNA-barcoded antibody sensing for photocleavable barcode detection without amplification.
- Benchmarked the technology in cell lines, achieving high reproducibility and single-cell sensitivity.
- Applied the method to profile approximately 90 proteins in FNA samples.
Main Results:
- Demonstrated high reproducibility and single-cell sensitivity in proteomic profiling of FNAs.
- Successfully mapped patient heterogeneity at the protein level using ~90 protein markers.
- Showcased the potential for clinical application in identifying drug pathway responses and predicting patient outcomes.
Conclusions:
- The developed DNA-barcoded antibody technology provides a sensitive and specific method for proteomic analysis of FNAs.
- This technique offers a powerful new tool for understanding cancer biology, patient stratification, and guiding clinical trial design.
